About
Technology
Issues
FAQ
Links
Official Page
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.